EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Targeting the TWEAK–Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury

Jonay Poveda, Laura González-Lafuente, Sara Vázquez-Sánchez, Elisa Mercado-García, Elena Rodríguez-Sánchez, Inés García-Consuegra, Ana Belén Sanz iD, Julián Segura, María Fernández-Velasco, Fernando Liaño, Luis M Ruilope, Gema Ruiz-Hurtado iD

The Journal of Pathology · 2023

DOI: 10.1002/path.6200 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Jonay Poveda and 11 co-authors. Institution: Cardiorenal Translational Laboratory, Institute of Research Imas12, Hospital Universitario 12 de Octubre, Madrid, Spain. Major MEDLINE topics: Calcium, Acute Kidney Injury. Cited 5 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Comunidad de Madrid, Instituto de Salud Carlos III, Ministerio de Universidades.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Heart and kidney have a closely interrelated pathophysiology. Acute kidney injury (AKI) is associated with significantly increased rates of cardiovascular events, a relationship defined as cardiorenal syndrome type 3 (CRS3). The underlying mechanisms that trigger heart disease remain, however, unknown, particularly concerning the clinical impact of AKI on cardiac outcomes and overall mortality. Tumour necrosis factor‐like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor‐inducible 14 (Fn14) are independently involved in the pathogenesis of both heart and kidney failure, and recent studies have proposed TWEAK as a possible therapeutic target; however, its specific role in cardiac damage associated with CRS3 remains to be clarified. Firstly, we demonstrated in a retrospective longitudinal clinical study that soluble TWEAK plasma levels were a predictive biomarker of mortality in patients with AKI. Furthermore, the exogenous application of TWEAK to native ventricular cardiomyocytes induced relevant calcium (Ca 2+ ) handling alterations. Next, we investigated the role of the TWEAK–Fn14 axis in cardiomyocyte function following renal ischaemia–reperfusion (I/R) injury in mice. We observed that TWEAK–Fn14 signalling was activated in the hearts of AKI mice. Mice also showed significantly altered intra‐cardiomyocyte Ca 2+ handling and arrhythmogenic Ca 2+ events through an impairment in sarcoplasmic reticulum Ca 2+ ‐adenosine triphosphatase 2a pump (SERCA 2a ) and ryanodine receptor (RyR 2 ) function. Administration of anti‐TWEAK antibody after reperfusion significantly improved alterations in Ca 2+ cycling and arrhythmogenic events and prevented SERCA 2a and RyR 2 modifications. In conclusion, this study establishes the relevance of the TWEAK–Fn14 pathway in cardiac dysfunction linked to CRS3, both as a predictor of mortality in patients with AKI and as a Ca 2+ mishandling inducer in cardiomyocytes, and highlights the cardioprotective benefits of TWEAK targeting in CRS3. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

CalciumAcute Kidney InjuryHumansMiceAnimalsTWEAK ReceptorRetrospective StudiesCytokine TWEAKTumor Necrosis FactorsMyocytes, Cardiac

Author keywords

TWEAK-Fn14 pathwayacute kidney injurycalcium mishandlingcardiomyocytecardiorenal syndromerenal ischaemia/reperfusion

Substances

CalciumTWEAK ReceptorCytokine TWEAKTumor Necrosis Factors

Authors and institutions

  • Cardiorenal Translational Laboratory, Institute of Research Imas12, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Proteomics Unit, Institute of Research Imas12, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Nephrology Laboratory, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid and REDINREN, Madrid, Spain.
  • Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • IdiPAZ Institute for Health Research/Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, CIBER-CV, Madrid, Spain.
  • Instituto Ramón y Cajal de Investigación Sanitaria (IRyCis), Madrid, Spain.

ORCID profiles: Ana Belén Sanz, Gema Ruiz-Hurtado

Funding

  • Comunidad de Madrid
  • Instituto de Salud Carlos III
  • Ministerio de Universidades
  • Ministerio de Ciencia e Innovación
  • the Education and Research Council of Madrid
  • Spanish Network in Inflammasoma and Pyroptosis in Chronic Disease and Cancer

Cite

APA

Poveda, J., González-Lafuente, L., Vázquez-Sánchez, S., Mercado-García, E., Rodríguez-Sánchez, E., García-Consuegra, I., Sanz, A. B., Segura, J., Fernández-Velasco, M., Liaño, F., Ruilope, L. M., & Ruiz-Hurtado, G. (2023). Targeting the TWEAK–Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury. The Journal of Pathology. https://doi.org/10.1002/path.6200

Vancouver

Poveda J, González-Lafuente L, Vázquez-Sánchez S, Mercado-García E, Rodríguez-Sánchez E, García-Consuegra I, et al. Targeting the TWEAK–Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury. The Journal of Pathology. 2023. doi:10.1002/path.6200

BibTeX
@article{Poveda2023,
  author = {Poveda, Jonay and González-Lafuente, Laura and Vázquez-Sánchez, Sara and Mercado-García, Elisa and Rodríguez-Sánchez, Elena and García-Consuegra, Inés and Sanz, Ana Belén and Segura, Julián and Fernández-Velasco, María and Liaño, Fernando and Ruilope, Luis M and Ruiz-Hurtado, Gema},
  title = {Targeting the TWEAK–Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6200}
}
Start for free →